Introduction {#s1}
============

Rab proteins, the biggest subfamily within the superfamily of small GTPases, are major regulators of vesicular trafficking in eukaryotic cells ([@bib49]). Like all small GTPases, Rab proteins cycle between an inactive GDP-bound and an active GTP-bound state. The cycling is tightly regulated and mediated by two families of enzymes: guanine nucleotide exchange factors (GEFs) that catalyze the GDP/GTP exchange and GTPase activating proteins that stimulate GTP hydrolysis ([@bib45]). Additionally, a variety of different effector proteins interact specifically with GTP-bound Rab proteins and mediate their versatile physiological roles in membrane trafficking, including budding of vesicles from a donor membrane, directed transport through the cell and finally tethering and fusion with a target membrane ([@bib12]). Especially in long-distance vesicular transport processes (e.g. in neuronal axons and dendrites), directed vesicular transport along cytoskeletal tracks appears to be an obvious mechanism and, consistently, different effector proteins have been reported to link Rab proteins to the cytoskeleton ([@bib22]; [@bib16]).

One such family of effector proteins that was reported to link Rab proteins and the cytoskeleton is the Mical (molecules interacting with CasL) family ([Figure 1](#fig1){ref-type="fig"}) ([@bib8]). Most of these Mical proteins contain an N-terminal monooxygenase domain that was reported to regulate actin dynamics via reversible oxidation of a methionine residue ([@bib17]; [@bib27]; [@bib18]). Additionally, all Mical proteins except the Mical C-terminal like protein (Mical-cL) contain a calponin homology (CH) and a Lin11, Isl-1 and Mec-3 (LIM) domain that have been reported to assist the interaction with actin and other cytoskeletal proteins, respectively ([@bib11]). Finally, all except Mical-2 contain a C-terminal coiled-coil domain that is also termed domain of unknown function (DUF) 3585 and that is known to interact with different Rab proteins ([@bib11]) ([Figure 1](#fig1){ref-type="fig"}).10.7554/eLife.18675.002Figure 1.Domain architecture of human proteins containing bMERB domains.Besides their C-terminal RBD (referred to as bivalent Mical/EHBP Rab binding (bMERB) domain), most Mical proteins contain an N-terminal Monooxygenase (red), a CH- and a LIM-domain (both orange). EHBPs also contain an actin binding CH-domain and an N-terminal membrane binding C2-domain (yellow) as well as a C-terminal prenylation motif (CaaX-box) following the bMERB domain. Two proteins predicted to contain only the bMERB domains (Mical-cL and C16orf45) are also shown. For proteins with multiple known splice variants, domain boundaries are indicated for isoform 1 (Mical-1: Uniprot ID Q8TDZ2, genomic location 6q21; Mical-L1: Uniprot ID Q8N3F8, genomic location 22q13.1; Mical-L2: Uniprot ID Q8IY33, genomic location 7p22.3; Mical-3: Uniprot ID Q7RTP6, genomic location 22q11.21; Mical-cL: Uniprot ID Q6ZW33, genomic location 11p15.3; EHBP1: Uniprot ID Q8NDI1, genomic location 2p15; EHBP1L1 Uniprot ID Q8N3D4, genomic location 11q13.1). The reader is referred to the main text for further details.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.002](10.7554/eLife.18675.002)

According to the SMART database ([@bib42]), this largely uncharacterized DUF3585 domain is present in more than 450 eukaryotic proteins (including 8 human proteins, see [Figure 1](#fig1){ref-type="fig"}). In humans, besides the Mical proteins this includes the family of EH (Eps15-homology) domain binding proteins (EHBPs) and one uncharacterized protein (C16orf45; see [Figure 1](#fig1){ref-type="fig"}). Interestingly, the EHBPs also contain a CH-domain and have been described to couple vesicular transport to the actin cytoskeleton ([@bib43]; [@bib13]).

Hitherto, the structural basis and the specificity of interaction between the Rab binding domains of Micals/EHBPs and Rab proteins remained largely unknown. In this publication, we have characterized the interaction of a number of these domains with Rab proteins extensively. Our results indicate preferential binding of this family of effector proteins to Rab proteins of the Rab8 family. Additionally, the results show that at least some of these effector domains can bind two Rab proteins simultaneously, suggesting a possible role as a Rab hub in vesicular trafficking.

In order to understand the structural basis of the interaction, we solved the first x-ray crystallographic structure of the RBD from the human protein Mical-3 and the first structures of different Rab proteins in complex with the RBDs of Mical-cL in a 1:1 stoichiometry and of Rab10 and the RBD of Mical-1 in a 2:1 stoichiometry.

This study is the first to show the structural basis of Rab proteins interacting with these RBDs and to systematically characterize the interaction with Rab proteins. Analysis of our data suggests that the second Rab binding site of these RBDs has evolved via a gene duplication event, indicating intriguing and hitherto unknown mechanisms of a concerted action of different Rab-regulated trafficking steps connected by these bivalent effector proteins, which we refer to as "bivalent Mical/EHBP Rab binding" (bMERB) domains ([Figure 1](#fig1){ref-type="fig"}). The study therefore substantially increases our understanding of Rab:effector interactions and will aid future research regarding the function of this diverse effector family.

Results {#s2}
=======

The bMERB domain preferentially binds Rab8 family proteins {#s2-1}
----------------------------------------------------------

Previously reported interactions of different bMERB domain containing proteins with Rab proteins included Rab1, Rab8, Rab10, Rab13, Rab15, Rab35 and Rab36 ([@bib11]; [@bib43]), although not all possible combinations of the effectors and the different Rab proteins were tested nor interactions quantified. We therefore set out to systematically confirm and quantify the interaction of 5 of these Rab proteins with the bMERB domains of Mical-1, Mical-3, Mical-cL, EHBP1 and EHBP1L1 via analytical size exclusion chromatography (aSEC) (see [Table 1](#tbl1){ref-type="table"}, the aSEC data is shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In these experiments, stable complex formation was detected with Rab8, Rab10, Rab13 and Rab15 (since Rab8, Rab10, Rab13 and Rab15 are closely related in amino acid sequence, we refer to them as the Rab8 family \[[@bib24]\]). Rab1, however, failed to form stable complexes with bMERB-domain proteins, indicating low affinity.10.7554/eLife.18675.003Table 1.Systematic analysis of interactions between Rab proteins and the bMERB domains of different proteins. Binding was systematically tested by analytical size exclusion chromatography (+ indicates binding in these experiments, − indicates that no complex formation was observed) and affinities were determined by ITC.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.003](10.7554/eLife.18675.003)**Mical-1Mical-3Mical-cLEHBP1EHBP1L1Rab1**\
**K~D~**+\
2.2 µM+\
2.6 µM+\
5.2 µM−\
\> 10 µM−\
\> 10 µM**Rab35**\
**K~D~**\
n.d.\
n.d+\
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n.d\
n.d**Rab8**\
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**K~D,2~**+\
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27.9 nM\
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n.d.+\
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n.d.+\
n.d.+\
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n.d.+\
n.d.**Rab15**\
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n.d.+\
n.d.+\
33 nM+\
n.d.+\
n.d.

In order to quantitatively verify the preference of the bMERB domain for Rab8 family members rather than Rab1 we performed isothermal titration calorimetry (ITC) measurements comparing the interaction of Rab1 and Rab8 with the different bMERB domains. Whereas we observed K~D~ values of 2.2--5.2 µM for Rab1 binding to the bMERB domains of Mical proteins and no detectable binding of Rab1 to the bMERB domains of EHBPs ([Table 1](#tbl1){ref-type="table"} and [Figure 2a](#fig2){ref-type="fig"}), we detected strong binding and ca. 100 nanomolar affinities for Rab8 and the different bMERB domains (see [Table 1](#tbl1){ref-type="table"} and [Figure 2b](#fig2){ref-type="fig"}). Using Mical-cL as one representative of the bMERB family, we saw that all members of the Rab8 family bound Mical-cL with high nanomolar affinities, compared to Rab1 (K~D~ = 5.2 µM) and Rab35 (K~D~ = 1.8 µM; [Table 1](#tbl1){ref-type="table"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The highest affinity observed was that of Rab15 and Mical-cL with a K~D~ of 33 nM. In accordance with the strong specificity of EHBPs towards the Rab8 family, Rab1a, Rab1b and Rab35 (a close relative of Rab1 which is also sometimes referred to as Rab1c) were previously shown not to interact with EHBP1/EHBP1L1 ([@bib43]; [@bib32]).10.7554/eLife.18675.004Figure 2.The bMERB domains preferentially interact with Rab8-family members.(**a**) Whereas Rab1 binds to Mical-1, Mical-3 and Mical-cL with low affinity and does not show detectable binding to EHBPs, (**b**) Rab8 binds with high affinity to all effector domains tested. Additionally, we observed two separate binding sites in the ITC experiments for Rab8 and Mical-1, Mical-3 and EHBP1L1 (the results of the binding fit including the stoichiometry, the K~D~, the binding enthalpy and the binding entropy are shown within the ITC spectra). (**c**) Mixing different ratios of Rab8 and the RBDs (1.2:1, 1.6:1 and 2.2:1), the 2:1 stoichiometry of binding was confirmed by aSEC for Rab8:Mical-1 and Rab8:EHBP1L1, whereas a 1:1 stoichiometry was observed for Rab8:Mical-3, Rab8:Mical-cL and Rab8:EHBP1L1 as indicated by a second peak corresponding to free excess Rab8. Note that the second low affinity binding site present in Mical-3 observed via ITC could not be detected via gel filtration.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.004](10.7554/eLife.18675.004)10.7554/eLife.18675.005Figure 2---figure supplement 1.Interaction of Rab proteins with the RBD of Mical-1, Mical-3, Mical-cL, EHBP1 and EHBP1L1.The Rab protein (130 µM, black) preparatively loaded with the non-hydrolyzable GTP-analogue GppNHp, the different bMERB domains (112.5 µM, red) and the mixture of both (130 µM Rab + 112.5 µM RBD) were subjected to analytical size exclusion chromatography (aSEC) and tested for complex formation between the RBDs (from left to right: Mical-1, Mical-3, Mical-cL, EHBP1, EHBP1L1) and the Rabs ((**a**) -- Rab1, (**b**) -- Rab8, (**c**) -- Rab10, (**d**) -- Rab13, (**e**) -- Rab15). Note the missing (Rab1:EHBP1 and Rab1:EHBP1L1) or incomplete (Rab1:Mical-3 and Rab1:Mical-cL) complex formation in (**a**) indicating low-affinity binding.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.005](10.7554/eLife.18675.005)10.7554/eLife.18675.006Figure 2---figure supplement 2.Interaction of Rab1, Rab35, Rab8, Rab10, Rab13 and Rab15 with Mical-cL.(**a**) The ITC data nicely show the relatively weak affinity of Rab1 towards Mical-cL (K~D~ = 5.2 µM) compared to Rab8 (K~D~ = 233 nM), Rab10 (K~D~ = 787 nM), Rab13 (K~D~ = 93 nM) and Rab15 (K~D~ = 33 nM). Rab35 (sometimes also referred to as Rab1c) has an intermediate affinity for Mical-cL (K~D~ = 1.8 µM). Since preparative loading of Rab35 with GppNHp (see below) was not successful, the concentration of the Rab35 protein fraction in the active state was deduced from HPLC analysis (see below) and the ITC data was corrected accordingly. (**b**) Comparison of the nucleotide status of Rab8 and Rab35 by HPLC analysis (black trace -- absorption at 254 nm, red trace -- absorption at 280 nm). The lower lane shows the trace of a nucleotide mix consisting of guanosine, GMP, GDP, GppNHp and GTP and a small impurity of GppNH~2~ as a reference, the retention times (in minutes) for each nucleotide are shown above the peak and in the table on the right. Whereas Rab8 could be preparatively loaded with GppNHp and analysis showed approximately 94% bound GppNHp, Rab35 was only 82% GppNHp-bound and the trace shows a major impurity of GppNH~2~ (18%). For this reason, the Rab35 protein concentration used in the ITC data in (**a**) was corrected for this.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.006](10.7554/eLife.18675.006)10.7554/eLife.18675.007Figure 2---figure supplement 3.Formation of a ternary complex between Rab8, Rab13 and the RBD of Mical1 or EHBP1L1.Rab8:GppNHp (130 µM, black), Rab13:GppNHp (130 µM, green) the different bMERB domains (112.5 µM, red) and the mixture of both (130 µM Rab + 112.5 µM RBD; dark blue for Rab8 and magenta for Rab13 in complex with the RBD) were subjected to analytical size exclusion chromatography (aSEC) and tested for complex formation between the Rabs and the RBDs. Additionally, the proteins were mixed in a ratio of 130 µM Rab8, 130 µM Rab13 and 112.5 µM RBD (light blue), clearly indicating that a 1:1:1 complex can be formed with 2 different Rab proteins bound to the respective RBDs.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.007](10.7554/eLife.18675.007)

EHBPs colocalize with Rab8-family members {#s2-2}
-----------------------------------------

Interestingly, in addition to the RBDs, EHBPs also contain CaaX-boxes at their C-termini (EHBP1: CVLQ; EHBP1L1: CVLS; [Figure 1](#fig1){ref-type="fig"}) for posttranslational modification with prenyl-groups. Therefore, we set out to test whether these motifs can be prenylated *in vitro* and if prenylation is responsible and necessary for correct intracellular localization. *In vitro*, both proteins can be farnesylated and geranylgeranylated by FTase and GGTase I, respectively. However, in accordance with the C-terminal amino acids of the CaaX-boxes being glutamine or serine ([@bib54]), we observed preferential farnesylation ([Figure 3a](#fig3){ref-type="fig"}). Using constructs containing the RBD with or without the CaaX-boxes, we next looked at the intracellular localization. These experiments clearly showed a CaaX-box dependent localization of both proteins to intracellular structures resembling endosomes ([Figure 3b](#fig3){ref-type="fig"}), as previously reported for the full length proteins ([@bib43]). Additionally, both proteins showed strong colocalization with constitutively active Rab8 and Rab10 (i.e. Rab8~Q67L~ and Rab10~Q68L~), both known to act at endosomes ([Figure 3c](#fig3){ref-type="fig"}), further supporting the function of this family of effector proteins as Rab8-family binding partners.10.7554/eLife.18675.008Figure 3.Prenylated EHBP1 and EHBP1L1 colocalize with Rab8 and Rab10.(**a**) EHBP1 and EHBP1L1 can be prenylated *in vitro* as shown by mass spectrometry. After incubation of the purified proteins including the CaaX-motifs (theoretical masses of the purified proteins: 22253.3 Da (EHBP1); 22214.0 Da (EHBP1L1); left panel) with Farnesytransferase (FTase, middle panel) or Geranylgeranyltransferase (GGTase, right panel) farnesylation/geranylgeranylation lead to an increase in mass of 205.4/272.5 Da, respectively. Note that farnesylation, in contrast to geranylgeranylation, appears to be more efficient under similar conditions and goes to completion. This is in agreement with the sequence of the CaaX-motifs in both proteins containing a Gln/Ser at their C-terminus which has been shown to favor farnesylation. (**b**) Whereas the constructs containing the bMERB domain and the CaaX-motif (EHBP1~1047-1231~, EHBP1L1~1340-1523~) localize to intracellular structures resembling endosomes, deletion of the CaaX-motif (∆CaaX) leads to a cytosolic distribution for both EHBP1 and EHBP1L1 (Scale bars: 10 µm). (**c**) Both EGFP-EHBP1~1047-1231~ and EGFP-EHBP1L1~1340-1523~ (upper panel) show strong colocalisation with mCherry-Rab8~Q67L~ and mCherry-Rab10~Q68L~ (middle panel) as indicated in the merged images (lower panel). The localization pattern resembles that of endosomes (Scale bars: 10 µm).**DOI:** [http://dx.doi.org/10.7554/eLife.18675.008](10.7554/eLife.18675.008)

Some bMERB domains can bind two Rab proteins simultaneously {#s2-3}
-----------------------------------------------------------

Besides the specificity of bMERB domains towards the Rab8 family, another interesting observation was made in the ITC experiments comparing the stoichiometry of binding of Rab8 and the different RBDs: Whereas Rab8 bound in a 1:1 stoichiometry to Mical-cL and EHBP1, a 2:1 stoichiometry binding was observed for Mical-1, Mical-3 and EHBP1L1 ([Table 1](#tbl1){ref-type="table"} and [Figure 2b](#fig2){ref-type="fig"}). For Rab8 and Mical-1/Mical-3, the ITC experiments show one high-affinity enthalpy-driven and one lower affinity entropy-driven binding site, compared to two binding sites with similar affinity for Rab8 and EHBP1L1.

In order to confirm the observed differences, we repeated the aSEC experiments with varying ratios of Rab8 and the different RBDs of Micals and EHBPs (1.2:1, 1.6:1 and 2.2:1; [Figure 2c](#fig2){ref-type="fig"}). These experiments clearly confirmed the aforementioned differences in the stoichiometry of binding with a 2:1 stoichiometry being observed for the Rab8:EHBP1L1 and Rab8:Mical-1 complexes, but not for others tested. The low affinity second binding site of Mical-3 (K~D~ = 4.4 µM as determined by ITC, [Table 1](#tbl1){ref-type="table"}) could also not be detected in these experiments, suggesting dynamic complex formation with a large k~off~. These data show that Mical-1 and EHBP1L1 contain two binding sites that bind Rab8 with high affinity, whereas Mical-3 (and possibly Mical-cL and EHBP1) contain one high affinity and a second lower affinity binding site for Rab8.

The presence of two distinct Rab binding sites on certain bMERB domains was a striking observation pointing towards a possible function of these effector proteins in sorting cargo and/or linking different endosomal trafficking pathways regulated by different Rab proteins. In accordance with this idea, recent studies on Mical-L2 dependent GLUT4 translocation showed that trafficking was dependent on a concerted action of Rab8 and Rab13 ([@bib46], [@bib47]). We consequently also tested whether the effector proteins might be able to simultaneously bind two different Rab proteins in a 1:1:1 (RabX:effector:RabY) complex using both Rab8 and Rab13 and the corresponding aSEC experiments clearly confirmed the formation of a ternary complex of Rab8:Mical-1:Rab13 as well as Rab8:EHBP1L1:Rab13 ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

The structural basis of Rab:bMERB interaction {#s2-4}
---------------------------------------------

In order to understand the mode of interaction of Rab proteins and the C-terminal Rab-binding domain of Micals/EHBPs, we first aimed at determining the structure of the RBD of one member of these families. We succeeded in crystallizing a selenomethionine derivative of Mical-3~1841-1990~ containing the whole predicted bMERB domain and solved the structure with a resolution of 2.7 Å (data and refinement statistics are shown in [Table 2](#tbl2){ref-type="table"}).10.7554/eLife.18675.009Table 2.Data-collection and processing statistics (values in parentheses are for the outer shell).**DOI:** [http://dx.doi.org/10.7554/eLife.18675.009](10.7554/eLife.18675.009) SeMet Mical-3~1841-19902~^†^Rab1:Mical-cL~534-683~Rab8:Mical-cL~534-683~**Data collection**^\*^X-Ray SourceX10SA at SLSX10SA at SLSX10SA at SLSWavelength (Å)0.9789560.999921.00009Resolution range (Å)47.8--2.7 (2.8--2.7)45.8--2.3 (2.4--2.3)46.0--2.85 (2.95--2.85)Space groupP 2~1~ 2~1~ 2~1~I 2 2 2C 2 2 2~1~Unit cell\
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The asymmetric unit contains two copies of Mical-3 that form a central 4-stranded coiled-coil composed of α-helices 2 and 3 of each monomer flanked by α-helices 1 on both sides ([Figure 4a](#fig4){ref-type="fig"}). Interactions between the monomers mainly occur via two hydrophobic patches and some additional charged interactions ([Figure 2b](#fig2){ref-type="fig"}). Overall, the structure shows that each monomer consists of a central helix (α2, residues K1891-R1937) and N- and C-terminal helices folding back on this central helix.10.7554/eLife.18675.010Figure 4.Structure of the Rab binding domain of Mical-3.Mical-3 folds into three α-helices, the central α-helix 2 and α-helices 1 and 3 folding back on the central helix. The dimer observed in the asymmetric unit is formed mostly by hydrophobic interactions involving the same hydrophobic patches in both monomers, and α-helices 2 and 3 from each monomer form a central 4-stranded coiled-coil.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.010](10.7554/eLife.18675.010)

The completely α-helical fold of this protein is common to many Rab effector proteins and most of them bind the interacting Rab proteins via two α-helices ([@bib30]). In order to test whether this is also true for the bMERB domains, we screened for crystallization conditions of bMERB:Rab complexes. Well diffracting crystals were found using the RBD of Mical-cL (residues 534--683) in complex with different Rab proteins (Rab1, Rab8 and Rab10). All structures were solved using a single chain of Mical-3 and the structure of Rab1 (pdb id 3nkv) or Rab8 (pdb id 4lhw) as search models for molecular replacement (the data collection and refinement statistics are shown in [Table 2](#tbl2){ref-type="table"}).

In all structures (Rab1:Mical-cL, Rab8:Mical-cL and Rab10:Mical-cL) we found one Rab protein bound to one molecule of Mical-cL ([Figure 5a](#fig5){ref-type="fig"}), in agreement with the previous observations that all Rab proteins tested bind only one site in Mical-cL. Most interactions were visible between the Rab proteins and α-helix 3 of Mical-cL with some additional contributing residues from α-helix 2, forming extensive contacts involving residues within switch I and II of the Rab proteins ([Figure 5b](#fig5){ref-type="fig"}). In all cases, hydrophobic interactions between the hydrophobic patch II in Mical-cL and residues from Rabs forming a hydrophobic pocket (residues Ile43, Phe70 and Ile73 in Rab8) and a triad of aromatic amino acids (Phe45, Trp62, Tyr77 in Rab8) known from all Rab:effector complexes solved to date ([@bib19]) were also observed in the Rab:Mical-cL structures.10.7554/eLife.18675.011Figure 5.The specificity of Rab proteins binding to bMERB domains.(**a**) A superposition of the complex structures of Rab1:Mical-cL, Rab8:Mical-cL, Rab10:Mical-cL and Rab1~R8N~:Mical-cL shows that Rabs bind Micals via their N-terminus (including RabSF1), RabSF2 as well as the switch regions (Rabs are shown in cartoon representation, switch I -- red, switch II -- blue, RabSF1 -- orange, RabSF2, magenta; Micals are shown in cartoon representation and colored in dark green (Mical-cL interacting with Rab1), yellow (Mical-cL interacting with Rab8), light green (Mical-cL interacting with Rab10) or brown (Mical-cL interacting with Rab1~R8N~). The sequence alignments of different Rab proteins clearly shows that the interacting residues of Rab proteins with Micals (red residues) are highly conserved (orange residues) in Rab1 and Rab8 family members (Rab1a, Rab1b, Rab35, Rab8, Rab10, Rab13, Rab15), but not in other Rabs (below the black line). (**b**) In all structures of Rab proteins in complex with Mical-cL, the N-termini of the Rab proteins point towards a negatively charged patch of Mical-cL (Rabs are shown in cartoon representation as above; the surface of Mical-cL is colored by charge, red -- negative charge, blue -- positive charge). The sequence of the N-terminal residues of each Rab protein is shown below the corresponding structure: Whereas Rab1 contains a negatively charged glutamate at position 4, Rab8 and Rab10 contain one or two lysine residues at position 3 or at position 3 and 4, respectively. Consistently, the negatively charged N-terminus of Rab1 seems to repel α-helices 1 and 2 of Mical-cL and they adopt a conformation slightly further away from Rab1 compared to Rab8 and Rab10 (also see (**a**)). However, after mutating the 4 N-terminal residues of Rab1 to the corresponding sequence of Rab8 (the resulting chimera is called Rab1~R8N~), the structure of Rab1~R8N~:Mical-cL shows a similar conformation of α-helices 1 and 2 as in the structure of Rab8:Mical-cL. (**c**) Consistently, ITC measurements show that the affinity of binding increases approximately five-fold after mutating the N-terminal residues (Rab1:Mical-cL: K~D~ = 5.2 µM; Rab1~R8N~:Mical-cL: K~D~ = 1.1 µM; Rab8:Mical-cL: K~D~ = 0.23 µM).**DOI:** [http://dx.doi.org/10.7554/eLife.18675.011](10.7554/eLife.18675.011)10.7554/eLife.18675.012Figure 5---figure supplement 1.The N-termini of Rabs determine the specificity towards bMERB domains.(**a**) Schematic presentation of the interactions between Rabs and Mical-cL (Switch I and II are shown in red and blue respectively; RabSF1, RabSF2 and RabF1 are shown in orange, magenta and green; Hydrophobic interactions are indicated by black dashed lines, ionic interactions and h-bonds are indicated by orange dashed lines). (**b**) Mutating the four N-terminal residues of Rab1 (1-MNPE...) to the sequence corresponding to Rab8 (1-MAKT...) leads to increased binding of EHBPs: Whereas Rab1 does not form a complex with EHBP1L1 (left) and EHBP1 (second from the right), the chimeric protein Rab1~R8N~ forms a complex with both (EHBP1L1, second from the left; EHBP1, right) as assessed by aSEC.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.012](10.7554/eLife.18675.012)10.7554/eLife.18675.013Figure 5---figure supplement 2.Comparison with other Rab:effector structures.The main interacting helix (α3) in the structure of Rab10:Mical-cL adopts a very similar relative position as the main interacting helices of the effector proteins in the structures of Rab3:Rabphilin-3a (pdb 1ZBD) ([@bib34]), Rab27:Slp2a (pdb 3BC1) ([@bib4]) and Rab27:Slac2-a (pdb 2ZET) ([@bib26]). Furthermore, a basic Arg and an acidic Asp are conserved in all structures (in Rab3:Rabphilin-3a, only the Arg is conserved) and contact the residues corresponding to Asp45 and Gln61 in Rab10.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.013](10.7554/eLife.18675.013)

Interestingly, the Rab-binding interface in Mical-cL has a substantial overlap with the dimer interface observed in the structure of Mical-3 above. Additionally, even though all Mical constructs used have a similar molecular weight of \~18 kDa, whereas Mical-1 runs as an apparent monomer in aSEC and binding of a Rab protein induces a clear shift to higher molecular weight, both Mical-3 and Mical-cL run as apparent dimers in aSEC and binding of a Rab protein disrupts the dimer, thus not leading to a shift in retention time upon complex formation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). It is however not clear at this point whether the dimer formation of Mical-3 and Mical-cL and the disruption of the dimer upon Rab-binding is of functional significance.

The specificity of effector proteins towards certain Rab families is generally achieved via interaction with regions termed Rab subfamily motifs (RabSFs) 1--4 ([@bib23]; [@bib29]; [@bib36]). In the Rab:Mical-cL structures, we observed extensive interaction of Mical-cL with RabSF1 (Tyr6, Asp7, Leu9, Lys11 in Rab10) and (less interactions) with RabSF2 (Asp31, Ser40 in Rab10). Accordingly, the sequence alignment of different Rab proteins ([Figure 5](#fig5){ref-type="fig"}) shows strong conservation of the interacting amino acids within these motifs amongst Rab1 (Rab1a/b, Rab35) and Rab8 (Rab8a/b, Rab10, Rab13, Rab15) family members that interact with bMERB domains, but not for other Rab proteins (a comparative scheme of the residues involved in interactions in the different complexes is shown in [Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}). Since the interacting residues in the RabSF1 and RabSF2 regions are strongly conserved between both Rab1 and Rab8 families, this did not explain the observed preference of the RBD towards the Rab8 family. However, we observed that the main chain atoms of the N-terminal residues preceding the RabSF1 motif can be traced in the electron density and seem to interact with amino acids within α-helix 1 and 2 of Mical-cL, even though the electron density in this region did not allow a precise localization of the side chains. In contrast to the main interacting helix α3, which adopts a similar position in all three structures, we observed slightly different orientations of the α-helices 1 and 2, adopting a position slightly further away from Rab1 compared to Rab8 and Rab10 ([Figure 5a](#fig5){ref-type="fig"}). Interestingly, whereas Rab1 contains a glutamate near the N-terminus (Glu4), all Rab8 family members contain one or (in the case of Rab10) two lysine residues in this region that point towards a negatively charged patch in Mical-cL ([Figure 5b](#fig5){ref-type="fig"}). Additionally, Rab35 contains an Arg residue within this N-terminal region and also displays a slightly higher affinity towards Mical-cL compared to Rab1 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We therefore tested whether these N-terminal residues of the Rab proteins might determine the specificity of bMERB domains towards Rab8 and its homologues rather than Rab1. We constructed a chimera of Rab1 containing the 4 N-terminal aa of Rab8, thus exchanging the negatively charged glutamate for a positively charged lysine. The x-ray crystallographic structure of this Rab1 chimera (termed Rab1~R8N~) in complex with Mical-cL clearly showed that the helices 1 and 2 move closer and adopt a similar conformation as observed in the structures of Rab8:Mical-cL and Rab10:Mical-cL ([Figure 5a](#fig5){ref-type="fig"}). Additionally, ITC measurements showed that the chimera had an approximately five-fold increased binding affinity compared to Rab1 ([Figure 5c](#fig5){ref-type="fig"}). In contrast to Rab1, the chimera Rab1~R8N~ bound both EHBP1 and EHBP1L1 in aSEC experiments ([Figure 5---figure supplement 1b](#fig5s1){ref-type="fig"}), thus clearly indicating that the N-terminus is important for the interaction and contributes to the observed specificity of bMERB domains towards Rab proteins.

The second Rab binding site has evolved by gene duplication {#s2-5}
-----------------------------------------------------------

Stimulated by the evidence for two Rab binding sites in some bMERB domains (Mical-1, Mical-3 and EHBP1L1), we searched for crystallization conditions of these RBDs with Rabs in a 1:2 stoichiometry. Crystallization conditions were found using a complex of Rab10~1--175~ and the RBD of Mical-1 (residues 918--1067), yielding crystals that diffracted to a resolution of 2.8 Angstrom at a synchrotron X-ray source and the resulting structure indeed showed two molecules of Rab10 bound to Mical-1 ([Figure 6a](#fig6){ref-type="fig"}). In addition to the binding site corresponding to the one previously observed in Mical-cL, an additional binding site was identified: Whereas this site is composed of the N-terminal half of the bMERB domain (α-helix 1 and the first half of α-helix 2), the Rab binding site observed in both Mical-1 and Mical-cL comprises the C-terminal half (second half of α-helix 2 and α-helix 3).10.7554/eLife.18675.014Figure 6.The two Rab binding sites are highly similar.(**a**) The structure of Mical-1 in complex with Rab10 shows two molecules of Rab10 bound to Mical-1 at different sites. Whereas one Rab protein binds to α-helix 1 and the first half of α-helix 2 (Mical-1~918-991~, binding site 1, blue), the second molecule of Rab10 binds the second half of α-helix 2 and α-helix 3 (Mical-1~994-1060~, binding site 2, green). Upon superimposition of both binding sites, the strong similarity becomes obvious and the helices from both binding sites adopt very similar positions. Furthermore, the interactions are highly similar in both cases as can be seen in the close-up view on the right (similar Rab-interacting residues within binding site 1 and 2 are shown in blue and green, respectively). (**b**) The strong conservation of interacting residues within both halves of the Mical-1 bMERB domain can also be seen in the sequence alignment of the N- and C-terminal halves. Additionally, the alignment shows that α-helix 1 and the first half of α-helix 2 (binding site 1) correspond to the second half of α-helix 2 and α-helix 3 (binding site 2), respectively (the secondary structure is indicated above and below the corresponding sequences, interacting and conserved residues within binding site 1 and 2 are highlighted in blue and green). (**c**) Whereas the whole bMERB domain of Mical-1 can bind two Rab molecules (left), deletion of either α-helix 1 (middle) or α-helix 3 (right) impairs binding to binding site 1 or 2, respectively. This effect could be shown both by aSEC and ITC (note the enthalpy-driven high-affinity binding site 2 and the entropy-driven lower-affinity binding site 1 that can be clearly distinguished, a schematic drawing of the different constructs is shown within the aSEC graphs). (**d**) Based on the observations made above, we propose that both binding sites must have evolved from a common ancestor by gene duplication of a 200 bp DNA fragment coding for the original gene product, a single α-hairpin. The fusion lead to the arrangement of the α-helices observed in bMERB domains, with the central α-helix 2 as a continuous connecting helix of both repeats, similar to the architecture of spectrin repeats.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.014](10.7554/eLife.18675.014)10.7554/eLife.18675.015Figure 6---figure supplement 1.Evolution of the second binding site.(**a**) Sequence alignments of the N- (blue) and C-terminal (green) halves of human bMERB domains made with Clustal Omega ([@bib44]). The residues in Mical-1 involved in binding Rab10 are shown in bold letters and the corresponding colors blue and green for binding site 1 and 2, respectively. In order to simplify comparison of the sequences, vertical lines are shown. The approximate positions of α-helices 1, 2 and 3 are also indicated. (**b**) Phylogenetic tree of the aligned sequences (the N- and C-terminal halves are again colored in blue and green, respectively). Uniprot accession IDs are Q8TDZ2 (Mical-1), Q8N3F8 (Mical-L1), Q8IY33 (Mical-L2), Q7RTP6 (Mical-3), Q6ZW33 (Mical-cL), Q8NDI1 (EHBP1) and Q8N3D4 (EHBP1L1).**DOI:** [http://dx.doi.org/10.7554/eLife.18675.015](10.7554/eLife.18675.015)10.7554/eLife.18675.016Figure 6---figure supplement 2.Structural comparison of the individual Rab binding sites in Mical-1.(**a**) Cartoon representation of the Rab10:Mical-1:Rab10 complex (centre) and selected close-up views (left and right). Left: Whereas Lys981 and Asn982 within the binding site (BS) 1 contact Asp45 and Gln61 in Rab10, the same residues in the other Rab10 molecule are contacted by Arg1044 and Asp1045 from BS2. Right: The hydrophobic residues Leu956~BS1~/Leu1011~BS2~, Val971~BS1~/Leu1034~BS2~, Leu975~BS1~/Val1038~BS2~ and Val978~BS1~/Val1041~BS2~ contacting Ile42~Rab10~, Ile44~Rab10~, Phe46~Rab10~, Trp63~Rab10~ and Ile74~Rab10~ (BS1, BS2 and Rab10 denote residues within binding site 1, binding site 2 or Rab10, respectively). (**b**) Schematic presentation of contacts between Rab10 and BS2 (left) or BS1 (right). Hydrophobic interactions are indicated by black dashed lines, ionic interactions and h-bonds are indicated by orange dashed lines.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.016](10.7554/eLife.18675.016)10.7554/eLife.18675.017Figure 6---figure supplement 3.Sequence alignment of the bMERB domains examined in this work.Residues known from the structures of Rab:bMERB complexes to make contacts with Rab proteins are highlighted in dark green (binding site 1) or dark orange (binding site 2). Conserved residues in other bMERB domains are colored light green or light orange, respectively. The approximate position of α-helices 1, 2 and 3 are indicated above the sequences. Uniprot accession IDs are Q8TDZ2 (Mical-1), Q8N3F8 (Mical-L1), Q8IY33 (Mical-L2), Q7RTP6 (Mical-3), Q6ZW33 (Mical-cL), Q8NDI1 (EHBP1) and Q8N3D4 (EHBP1L1).**DOI:** [http://dx.doi.org/10.7554/eLife.18675.017](10.7554/eLife.18675.017)

Upon closer inspection and alignment, a strong similarity between the two Rab binding sites in Mical-1 became obvious, involving the same/similar residues both within the two different molecules of Rab10 as well as the two binding sites in Mical-1, respectively ([Figure 6a](#fig6){ref-type="fig"}). An alignment of the sequences of the corresponding N- and C-terminal halves of all different Micals (Mical-1, Mical-cL, Mical-3, Mical-L1 and Mical-L2), EHBP1 and EHBP1L1 (see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, the example for Mical-1 is shown in [Figure 6b](#fig6){ref-type="fig"}) with Clustal Omega ([@bib44]) highlights the striking similarity between the binding sites and shows the strong conservation of Rab-interacting residues within the two binding sites. A non-exhaustive list and a close-up view of several of these interactions is shown in [Table 3](#tbl3){ref-type="table"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}, respectively. It should be noted that use of the N- and C-terminal halves of only one of the bMERB domains was not sufficient for Clustal Omega alignment to converge and find the conserved residues within the separate halves. In contrast, the webserver HHrepID ([@bib2]) nicely predicted and aligned the two repeats present in Mical-1 with a p-value of 1.1^--5^.10.7554/eLife.18675.018Table 3.Non-exhaustive list of conserved interactions between Rab10 and the separate binding sites in Mical-1.**DOI:** [http://dx.doi.org/10.7554/eLife.18675.018](10.7554/eLife.18675.018)**Mical-1Rab10Binding site 1Binding site 2**Glu964Glu1030Arg70Lys981Arg1044Asp45Asn982Asp1045Gln61Leu956Leu1011Ile42Val971Leu1034Ile42Leu975Val1038Ile44, Ile74Val978Val1041Ile44, Phe46, Trp63Val985Ile1048Leu9, Phe46, Ile48

Consistent with the localization of the two separate binding sites within the N-terminal and the C-terminal half of the bMERB domain, respectively, deletion constructs lacking either α-helix 1 (Mical~960--1067~) or α-helix 3 (Mical-1~918--1020~) displayed a clear 1:1 stoichiometry of Rab binding both in aSEC and ITC experiments ([Figure 6c](#fig6){ref-type="fig"}). Furthermore, the ITC data allowed us to clearly allocate the high affinity binding to the C-terminal binding site and the lower affinity binding to the N-terminal binding site.

In summary, the strong conservation of interacting residues between both sites as well as the structural conservation of the binding sites lead us to conclude that this family of Rab binding proteins must have evolved via gene duplication ([Figure 6d](#fig6){ref-type="fig"}). Furthermore the strong conservation of interacting residues not only between the two separate binding sites in Mical-1, but also between the different bMERB domains (see alignments in [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [3](#fig6s3){ref-type="fig"}) suggests that all of these proteins contain a second (possibly low affinity) binding site. Further analysis of the Rab specificity of both sites within these proteins will therefore be of great interest.

Discussion {#s3}
==========

In this publication, we present a thorough biochemical and structural analysis of a Rab effector domain termed bivalent Mical/EHBP Rab binding (bMERB) domain. The results show that the domains probably constitute a Rab8-effector family involved in endosomal trafficking, and the Rab-binding specificity can be well explained from the 3-dimensional structures of complexes determined in this work. Furthermore, we show that at least some of these domains contain two separate binding sites for Rab-proteins, suggesting previously unknown functions, as discussed below. The strong similarity between the 2 binding sites within one effector domain strongly suggests an evolutionary development via gene duplication.

The high specificity of the effector domains towards Rab8 family members can be well explained from the structural analysis of Rab:bMERB complexes. Specificity-determining interactions were seen between the effector domains and the RabSF1 and RabSF2 motifs. However, additional interactions were required to increase the specificity even further, thus allowing the proteins to distinguish Rab1- and Rab8-family members. In this regard, we showed that the N-terminal residues preceding the RabSF1 motif contribute to this specificity, an observation that has previously not been made in other Rab:effector interactions. However, as alluded to in the introduction, the presence of multiple isoforms (e.g. Mical-1, Mical-L1 etc.) of the proteins, as well as the demonstrated presence of two separate binding sites, might also point towards a broader and more diverse Rab-binding spectrum and is the subject of ongoing research in our work.

The 3-dimensional structures of the effector domains solved in this work showed a solely α-helical fold common to many other Rab effector proteins ([@bib33]). Further comparison with other known Rab:effector structures showed that the main interacting helix in Rab:bMERB complexes (e.g. α-helix 3 in Mical-cL) adopts a similar position to that of the main interacting helix in the structures of Rab27:Slp2-a ([@bib4]), Rab27:Slac2a/melanophilin ([@bib26]) and Rab3:Rabphilin-3a ([@bib34]) (see [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} for a comparison). Interestingly, in all three examples, the Arg/Lys contacting Asp45 in our Mical:Rab structures is also conserved in these effector proteins, and the Asp/Asn following this basic residue and contacting Gln61 in Rabs is conserved in both Slp2-a and Slac2a. Intriguingly, these effector domains also display similar binding affinities as bMERB domains towards their cognate Rabs (K~D~ = 13.4 nM for Rab27:Slp2-a, K~D~ = 112 nM for Rab27:Slac2-a/melanophilin) ([@bib9]), and these are amongst the highest affinities observed for Rab:effector interactions.

Both the biochemical as well as the structural analysis identified a second binding site in Mical-1, Mical-3 and EHBP1L1, thus allowing these effectors to bind Rab proteins in a 1:2 stoichiometry. In contrast to the bMERB domain proteins, Rab:effector complexes that were previously characterized display either a 1:1 or 2:2 stoichiometry, where the 2:2 complexes are usually formed by a central effector dimer with symmetrical binding interfaces on both sites ([@bib33]). On the other hand, multivalent Rab effector proteins have been described previously (examples are Rab4 and Rab5 binding to Rabaptin-5 ([@bib51]), Rab6 and Rab11 binding to Rab6IP1 ([@bib28]) or the extreme case of Gcc185 with five sites binding to Rab1a/b, Rab2a/b, Rab6a/b, Rab9a/b, Rab15, Rab27, Rab30, Rab33, Rab35 and Rab36 ([@bib15]). However, all of these effectors contain separate Rab-binding domains, each in turn only binding one Rab protein. The work presented constitutes the first description of two Rab proteins binding a single effector domain.

The separate binding sites within one domain not only represent a novel finding for Rab effector molecules, but also suggest intriguing and hitherto unknown functions of these proteins. Such functions could include linking Rab-decorated vesicles to a target membrane or other vesicles via a central bivalent effector. On the other hand, concerted Rab cascades and feedback loops have been observed with effector domains fused to GEFs or GAPs of one Rab acting upstream or downstream of a second Rab, helping to recruit or remove Rab proteins from a certain membrane ([@bib37]). Bivalent effectors could act in a similar manner in a positive feedback loop, initially being recruited by activated Rab proteins and subsequently helping in the recruitment and stabilization of further Rabs at this site to establish Rab membrane microdomains ([@bib37]). In fact, the presence of one high affinity and one low affinity Rab binding site as observed in some bMERB effectors could further enhance the formation of Rab microdomains: Whereas the Rab bound to the high affinity site would essentially stay bound within physiologically relevant timescales, the additional Rab protein recruited by the low affinity site could dissociate again and recruit another effector molecule via the high affinity site, thus helping to concentrate Rabs within small areas on the membrane.

Additionally and similar to the suggested function of Rab6IP linking Rab6 and Rab11 mediated vesicular trafficking events ([@bib28]), bMERB domain containing effectors might fulfill analogous functions in vesicular trafficking and act as effector Rab hubs. The possible importance of such concerted membrane recruitment cascades of Rabs and other proteins involved in membrane trafficking has been previously highlighted for Mical-L1 connecting Rab35 and Rab8, and this was aptly referred to as a membrane hub ([@bib38]; [@bib10]). Furthermore, recent studies on Mical-L2 dependent GLUT4 translocation showed that trafficking was dependent on a concerted action of Rab8 and Rab13 ([@bib46], [@bib47]). In another study it was shown that Mical-L1 is recruited to recycling endosomes by Rab35 and subsequently recruits other Rab proteins (Rab8, Rab13 and Rab36) ([@bib25]). In this work, the authors concluded that dimerization of Mical-L1 allows a concerted recruitment and binding of two separate Rabs to an effector dimer. However, our data now show how the 2 separate binding sites presumably also present in Mical-L1 and Mical-L2 (see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) could help in establishing this concerted action of two Rabs by connecting them via one bivalent effector protein in an (intermediate) 1:1:1 complex, thus explaining for the first time the structural and biochemical basis of the Rab hub function. The strong sequence homology of different bMERB domains including both binding sites and the fact that all Rab8 family proteins reported to interact with Micals/EHBPs are implicated in different steps of endocytic trafficking ([@bib52]) as well as previously published data thus points towards an important function of Micals/EHBPs in sorting of endocytic cargo with different destinations in the cell.

Another possible functional implication of the separate binding sites follows from the observation of an auto-inhibited state within Micals. Previous studies have shown that the bMERB domains in Micals can bind to their CH/LIM domains, forming an auto-inhibited intramolecular interaction that can be released by competitive binding of Rab proteins, thus allowing for the interaction with actin only after binding of Rabs ([@bib47]; [@bib39]; [@bib40]). The structural basis as well as the functional significance of this competitive binding will be an interesting topic for future research, especially regarding the binding region at the RBD responsible for auto-inhibition. The two binding sites might therefore also have separate functions, serving as a membrane recruitment site by Rabs via one site (presumably the high-affinity binding site) and release of the auto-inhibition due to competitive binding of the CH/LIM domains and Rabs at the second binding site.

In the last part of the study, we have shown that the two binding sites share a strong similarity and bind Rab proteins via similar residues within the interaction surfaces, thus indicating that the RBD have evolved via duplication of a common ancestor supersecondary structure element ([Figure 6d](#fig6){ref-type="fig"}) ([@bib48]). The underlying single α-hairpin motifs making up the separate Rab-binding sites are known from other Rab-effectors such as Rabenosyn-5 ([@bib23]; [@bib6]), and the resulting fused α-hairpins observed in Micals and EHBPs strongly resemble the architecture of spectrin repeats, each being connected via one continuous helix ([@bib14]; [@bib35]). Because of the strong similarity between the repeats of the different isoforms of Micals and EHBPs, but less similarity between both repeats within the bMERB domains ([Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"}), we suggest that the duplication must have occurred early in evolution in one common ancestor bMERB domain. The two repeats have since diverged in terms of overall sequence, but the ability to bind Rab proteins has remained in at least some cases, as shown in this study. Exploration of the binding specificity of both binding sites of the bMERB proteins towards Rabs (and possibly other GTPases \[[@bib38]\]) will therefore be of great interest.

Materials and methods {#s4}
=====================

Protein expression and purification {#s4-1}
-----------------------------------

Rab proteins were expressed and purified as described previously (Rab1 \[[@bib41]\] and other Rab proteins \[[@bib3]\]) and preparatively loaded with GppNHp (Guanosine-5'-\[β-γ-Imido\]-triphosphat) for interaction studies with their effector proteins. For this purpose, the proteins were incubated in the presence of 5 mM EDTA, 5--10% glycerol, three-fold molar excess of GppNHp over the Rab protein and 0.5 units alkaline phosphatase per mg Rab protein for 2 hr at 20°C or at 4°C overnight. Subsequently the proteins were purified via gel filtration in a buffer containing 20 mM Hepes pH 7.5, 50 mM NaCl, 2 mM DTE, 2 mM MgCl~2~ and 10 µM GppNHp. bMERB domains (amino acid boundaries and Uniprot accession IDs are shown in [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}) were cloned into a modified pET19 expression vector and proteins were expressed in *E. coli* BL21 DE3 RIL cells (growth at 37°C to OD~600 nm~ = 0.8--1.0, stored at 4°C for 30 min, expression was induced by addition of 0.3--0.5 mM IPTG and cells were grown for 14--18 hr at 20°C). Subsequently the proteins were purified by Ni^2+^-affinity chromatography, cleavage of the His~6~-tag with TEV-protease and a second Ni^2+^-affinity purification. Final purification was achieved by gel filtration (Rabs: 20 mM Hepes pH 7.5, 50 mM NaCl, 2 mM DTE, 2 mM MgCl~2~, 10 µM GDP or GppNHp; Micals: 20 mM Hepes pH 7.5, 50 or 100 mM NaCl, 2 mM DTE). In order to express the selenomethionine labeled version of the coiled coil domain of Mical-3, the methionine biosynthesis inhibition method ([@bib50]) was used. The labeled protein was purified as described above. FTase and GGTase I were purified as described previously ([@bib5]; [@bib21]).

For prenylation, EHBP1~1047-1231~/EHBP1L1~1340-1523~, substrate (farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP); Sigma) and prenyltransferase (FTase or GGTase I) were mixed in a 1:5:0.5 ratio in buffer containing 25 mM Hepes pH 7.2, 40 mM NaCl and 2 mM MgCl~2~ and incubated for 3 hr at room temperature. To check the extent of prenylation, samples were analyzed by ESI-MS.

Analytical size exclusion chromatography {#s4-2}
----------------------------------------

Complex formation of Rab proteins preparatively loaded with GppNHp and the bMERB effector domains was assessed by analytical size exclusion chromatography (aSEC). The effector domains were used at a concentration of 113 µM, Rab proteins were used at concentrations of 130 µM (Rab:effector stoichiometry of 1.2:1), 180 µM (1.6:1) or 250 µM (2.2:1) and 30 µl of the protein solutions were injected into a Superdex S75 10/300 GL gel filtration column (flow rate 0.5 ml/min, detection of absorption at 280 nm, buffer: 20 mM Hepes pH 7.5, 50 mM NaCl, 2 mM DTE, 2 mM MgCl~2~).

Isothermal titration calorimetry {#s4-3}
--------------------------------

Protein-protein interaction was studied by ITC using an iTC~200~ microcalorimeter (MicroCal). Measurements were performed in buffer containing 20 mM Hepes pH 7.5, 50 mM NaCl, 2 mM MgCl~2~ and 1 mM tris (2-carboxymethyl) phosphine (TCEP) at 25°C and for every experiment a technical replicate was performed. 400 µM Rab was titrated into the cell containing 20--40 µM of Mical. Data were analyzed with Origin (Version 7.0, MicroCal).

X-ray crystallography {#s4-4}
---------------------

Initial crystallization conditions for single effector proteins and all protein complexes described here were determined with the JSG Core I-IV, Pact and Protein Complex suites from Qiagen. The sitting-drop vapor diffusion method was used, with a reservoir volume of 70 μl and a drop volume of 0.1 μl protein (15--25 mg ml^−1^) and 0.1 μl reservoir solution at 20°C. The best conditions were then optimized using the hanging-drop vapor diffusion method in order to obtain well diffracting crystals. The seleno-L-methionine labelled Mical-3~1841--1990~ was finally crystallized in 0.1 M Tris pH 7.0 und 45 -- 50% PEG 200 (protein concentration 5.5 -- 11 mg/ml). Mical-cL~534--683~ in a 1 to 1 complex ratio with all tested Rab proteins crystallized in similar conditions. The complex with Rab1b~Fl~ was crystallized in 0.1 M bis-tris-propane pH 8.4--8.6, 0.2 M tri-sodium citrate and 20--22% (w/v) PEG 3350, with Rab8a~Fl~ in 0.1 M bis-tris-propane pH 8.3--8.7, 0.2 M tri-sodium citrate and 18--20% (w/v) PEG 3350 and finally with Rab10~Fl~ in 0.2--0.3 M sodium acetate and 18--22% (w/v) PEG 3,350. The hybrid Rab1b~R8N~ (chimera) in complex with Mical-cL~534--683~ was crystallized in 0.1 M bis-tris pH 7.5, 0.2 M sodium malonate and 20% (w/v) PEG3350. Mical-1~918--1067~ crystallized with Rab10~1-175~ in a 1 to 2 ratio under the following conditions: 0.1 M imidazole pH 7.6--8.0 and 6--10% (w/v) PEG 8,000.

Best diffracting crystals were flash-cooled in liquid nitrogen and diffraction data were collected on beamline X10SA at the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) and processed with XDS ([@bib20]). The structure of Mical-3~1841--1992~ was solved by the single anomalous diffraction method using data collected at the selenium absorption edge. Initial phases and an initial model were obtained with PHENIX AutoSol ([@bib1]). All protein complex structures were solved by the maximum likelihood molecular replacement method using the structures of Mical-3~1841--1992~, Mical-cL~534--683,~ Rab1b (pdb id 3nkv) and Rab8a (pdb id 4lhw) as search models. The initial structure models were completed by hand in Coot ([@bib7]) and refined with phenix.refine ([@bib1]) or Refmac5 ([@bib31]) of the CCP4 package ([@bib53]) using the TLS option. Data collection and refinement statistics, as well the Protein Data Bank accession numbers of each presented structure are summarized in [Table 1](#tbl1){ref-type="table"}.

Fluorescence microscopy {#s4-5}
-----------------------

Rab constructs were cloned into pmCherry vector using the XhoI and BamHI restriction sites and to obtain active Rab mutants (Rab8~Q67L~, Rab10~Q68L~) quick change mutagenesis was performed. Further EHBP1~1047-1231,~ EHBP1~1047-1227~ (missing the CaaX-box), EHBP1L1~1340-1523~ and EHBP1L1~1340--1519~ (missing the CaaX-box) constructs were cloned into pEGFP(C1) vector between EcoRI and SalI sites.

Cos7 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and penicillin/streptomycin at 37°C in the presence of 5% CO~2~. Cells were grown on a coverslip in 6 well plate until they reached 60--70% confluency and transiently transfected using polyethylenimine (PEI, Polysciences,Inc, 3∶1 PEI:DNA (12∶4 µg). Expression was checked 20--24 hr post transfection. Cells were fixed with 3.7% paraformaldehyde in PBS for 15 min at room temperature. Unreacted paraformaldehyde was quenched with 100 mM glycine in PBS for 15 min. After washing with PBS, cover slips were mounted on glass slides with SlowFade Gold antifade reagent (Invitrogen). Images were taken using a Leica TCS SP8 confocal microscope, 63 × 1.4 NA HC PL APO CS2 oil immersion objective. For Delta CaaX constructs single plane images were taken and for 3D reconstitutions, three dimensional stacks with 0.3-μm steps were acquired. Images from the all focal planes were rendered as a single maximum-intensity projection using Leica software.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"bMERB domains are bivalent Rab8 effectors evolved by gene duplication\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Reinhard Jahn, is a member of our Board of Reviewing Editors and the evaluation has been overseen by John Kuriyan as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript includes a thorough biochemical and structural characterization of the interaction between Rab8 family proteins and an effector domain shared by the MICAL and EHBP1 protein families. All reviewers agree that the work is of very high quality and that the manuscript is excellent. For these reasons, the reviewers do not request additional experiments but rather ask for considering the (rather minor) issues raised by Reviewers 2 and 3. This also includes a possible change of the title of the manuscript as suggested by Reviewer 3. Please note, however, that none of these suggested changes is mandatory for acceptance.

Reviewer \#2:

a\) The authors state in the Abstract that their study is \"the first to thoroughly characterise a Rab effector domain that contains two separate binding sites\". This is potentially confusing as of course several Rab effectors are dimeric and so contain two separate binding sites in the dimer. The text needs to be clarified.

b\) [Figure 1](#fig1){ref-type="fig"}. Are all eight proteins from separate genes or are some alternatively spliced transcripts from the same gene? This should be made clear in the text and figure.

c\) [Figure 3](#fig3){ref-type="fig"}. The Mical-3 bMERB domain is a dimer in the crystal. Is it also a dimer in solution? Also, is it still a dimer when co-crystalised with the Rabs in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}? This is an important point which needs to be discussed clearly in the text.

d\) Results section: The \"non-exhaustive list of conserved interactions\" could instead be presented as a table rather than in a long sentence.

*Reviewer \#3:*

As currently written the title implies that bMERB8 proteins are Rab8 effectors, rather than effectors for the wider Rab8 family of GTPases (8/10/13/15). The data presented in [Table 1](#tbl1){ref-type="table"}, although not complete, indicate that Rab13 and Rab15 might be the preferential partners for Mical-cL. [Figure 6](#fig6){ref-type="fig"} shows a structure with Rab10 and Mical-1 rather than Rab8. In the absence of further functional data linking the various Rabs to the effectors, the title should be made more general and refer to the Rab8 subfamily of GTPases. The Abstract should also specifically mention which Rab GTPases the authors have looked at: Rab8/10/13/15. Writing \"Rab8 family proteins\" might be interpreted as meaning only Rab8A and 8B by less careful readers.

I don\'t follow the logic of the statement at the end of the Abstract: \"a Rab effector domain that contains two separate binding sites, allowing Micals and EHBPs to bind two Rabs simultaneously and thus suggesting novel and previously unknown functions of these effector molecules in endosomal trafficking\". If these were GTPases of different families, e.g. Rab and Rho or Ras, then the argument would be clear. However, binding multiple Rabs still implies a link to functions in membrane trafficking rather than other cellular processes. What is novel or unknown in that sense? I agree with the view that I suspect informs this statement, which is that we don\'t really understand what the Mical/EHBP proteins do, or how Rab-binding controls their function. Multivalent Rab binding might allow one effector integrate inputs from different Rabs at one membrane or perhaps different membranes bearing different Rabs. Perhaps something along these lines could be referred to at the end of the Abstract.

Why was Rab35 not investigated? Given the extensive characterisation of interactions with the related Rabs this is an obvious omission.

EHBP1 prenylation data and membrane targeting in [Figure 3](#fig3){ref-type="fig"} are interesting but don\'t fit with the main thrust of the work that is focussed on the Rab-effector interaction. This would be better as supplemental information for [Figure 1](#fig1){ref-type="fig"}.

[Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. Labelling of residues in the bMERB8 domains are too small to read.
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Author response

*This manuscript includes a thorough biochemical and structural characterization of the interaction between Rab8 family proteins and an effector domain shared by the MICAL and EHBP1 protein families. All reviewers agree that the work is of very high quality and that the manuscript is excellent. For these reasons, the reviewers do not request additional experiments but rather ask for considering the (rather minor) issues raised by Reviewers 2 and 3. This also includes a possible change of the title of the manuscript as suggested by Reviewer 3. Please note, however, that none of these suggested changes is mandatory for acceptance.*

*Reviewer \#2:*

*a) The authors state in the Abstract that their study is \"the first to thoroughly characterise a Rab effector domain that contains two separate binding sites\". This is potentially confusing as of course several Rab effectors are dimeric and so contain two separate binding sites in the dimer. The text needs to be clarified.*

In order to clarify this point we have rephrased the sentence in the Abstract:

"This study is the first to thoroughly characterise a Rab effector protein that contains two separate Rab binding sites within a single domain, allowing \[...\]\".

*b) [Figure 1](#fig1){ref-type="fig"}. Are all eight proteins from separate genes or are some alternatively spliced transcripts from the same gene? This should be made clear in the text and figure.*

They are all from separate genes. To clarify this we have added the following information in the figure legend:

"For proteins with multiple known splice variants, domain boundaries are indicated for isoform 1 (Mical-1: Uniprot ID Q8TDZ2, genomic location 6q21; Mical-L1: Uniprot ID Q8N3F8, genomic location 22q13.1; Mical-L2: Uniprot ID Q8IY33, genomic location 7p22.3; Mical-3: Uniprot ID Q7RTP6, genomic location 22q11.21; Mical-cL: Uniprot ID Q6ZW33, genomic location 11p15.3; EHBP1: Uniprot ID Q8NDI1, genomic location 2p15; EHBP1L1 Uniprot ID Q8N3D4, genomic location 11q13.1)."

*c) [Figure 3](#fig3){ref-type="fig"}. The Mical-3 bMERB domain is a dimer in the crystal. Is it also a dimer in solution? Also, is it still a dimer when co-crystalised with the Rabs in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}? This is an important point which needs to be discussed clearly in the text.*

Indeed, both Mical-3 and Mical-cL appear to form dimers in solution, whereas Mical-1 does not. However, we can currently not comment on any physiological significance of this. We have added one paragraph in order to clarify this point:

"Interestingly, the Rab-binding interface in Mical-cL has a substantial overlap with the dimer interface observed in the structure of Mical-3 above. Additionally, even though all Mical constructs used have a similar molecular weight of \~18 kDa, whereas Mical-1 runs as an apparent monomer in aSEC and binding of a Rab protein induces a clear shift to higher molecular weight, both Mical-3 and Mical-cL run as apparent dimers in aSEC and binding of a Rab protein disrupts the dimer, thus not leading to a shift in retention time upon complex formation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). It is however not clear at this point whether the dimer formation of Mical-3 and Mical-cL and the disruption of the dimer upon Rab-binding is of functional significance."

d\) Results section: The \"non-exhaustive list of conserved interactions\" could instead be presented as a table rather than in a long sentence.

According to the reviewers' suggestion we have added [Table 3](#tbl3){ref-type="table"} and changed the manuscript accordingly:

"A non-exhaustive list and a close-up view of several of these interactions is shown in [Table 3](#tbl3){ref-type="table"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}, respectively."

*Reviewer \#3:*

*As currently written the title implies that bMERB8 proteins are Rab8 effectors, rather than effectors for the wider Rab8 family of GTPases (8/10/13/15). The data presented in [Table 1](#tbl1){ref-type="table"}, although not complete, indicate that Rab13 and Rab15 might be the preferential partners for Mical-cL. [Figure 6](#fig6){ref-type="fig"} shows a structure with Rab10 and Mical-1 rather than Rab8. In the absence of further functional data linking the various Rabs to the effectors, the title should be made more general and refer to the Rab8 subfamily of GTPases. The Abstract should also specifically mention which Rab GTPases the authors have looked at: Rab8/10/13/15. Writing \"Rab8 family proteins\" might be interpreted as meaning only Rab8A and 8B by less careful readers.*

According to the reviewers' suggestion we have updated the title ("bMERB domains are bivalent Rab8 family effectors evolved by gene duplication") and additionally modified the Abstract:

"Within our study, we show that these effectors display a strong preference for Rab8 family proteins (Rab8, 10, 13 and 15) and that some of the effector domains can bind two Rab proteins \[...\]".

*I don\'t follow the logic of the statement at the end of the Abstract: \"a Rab effector domain that contains two separate binding sites, allowing Micals and EHBPs to bind two Rabs simultaneously and thus suggesting novel and previously unknown functions of these effector molecules in endosomal trafficking\". If these were GTPases of different families, e.g. Rab and Rho or Ras, then the argument would be clear. However, binding multiple Rabs still implies a link to functions in membrane trafficking rather than other cellular processes. What is novel or unknown in that sense? I agree with the view that I suspect informs this statement, which is that we don\'t really understand what the Mical/EHBP proteins do, or how Rab-binding controls their function. Multivalent Rab binding might allow one effector integrate inputs from different Rabs at one membrane or perhaps different membranes bearing different Rabs. Perhaps something along these lines could be referred to at the end of the Abstract.*

Indeed we agree that they presumably have a function in endosomal vesicular trafficking (we stated "suggesting novel and previously unknown functions of these effector molecules in endosomal trafficking.\"). However, the presence of two separate binding sites implies that (for as yet unknown reasons) these effectors bind two different Rab proteins simultaneously. As we discuss later in the manuscript, this might include functions "in sorting cargo and/or linking different endosomal trafficking pathways regulated by different Rab proteins", however we have no experimental data at this point that would allow us to do more than speculate.

*Why was Rab35 not investigated? Given the extensive characterisation of interactions with the related Rabs this is an obvious omission.*

Rab35 was actually investigated, however upon preparative nucleotide exchange of Rab35 with GppNHp, the protein selectively bound and enriched an impurity present in the commercially available GppNHp, the hydrolysis product GppNH~2~. Because of these problems with preparative loading of the protein with GppNHp the data was not included in the first version of the paper. We have however now included data for Rab35 and Mical-cL in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, including the data about preparative GppNHp binding.

We also updated the main manuscript (including [Table 1](#tbl1){ref-type="table"}) accordingly:

"Using Mical-cL as one representative of the bMERB family, we saw that all members of the Rab8 family bound Mical-cL with high nanomolar affinities, compared to Rab1 (K~D~ = 5.2 µM) and Rab35 (K~D~ = 1.8 µM; [Table 1](#tbl1){ref-type="table"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"})".

"Mical-cL ([Figure 5, b](#fig5){ref-type="fig"}). Additionally, Rab35 contains an Arg residue within this N-terminal region and also displays a slightly higher affinity towards Mical-cL compared to Rab1 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We therefore tested whether these N-terminal \[...\]".

*EHBP1 prenylation data and membrane targeting in [Figure 3](#fig3){ref-type="fig"} are interesting but don\'t fit with the main thrust of the work that is focussed on the Rab-effector interaction. This would be better as supplemental information for [Figure 1](#fig1){ref-type="fig"}.*

We feel that the information does fit the main thrust of the work since we argue that DUF3585 bMERB domains are Rab8 family effectors. Therefore, *in vivo* localization studies showing that EHBP1 and EHBP1L1 colocalize with Rab8 family members at endosomes strengthens this point and we would therefore like to keep [Figure 3](#fig3){ref-type="fig"} as it is.

*[Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. Labelling of residues in the bMERB8 domains are too small to read.*

We have increased the font size in the corresponding figures.

In addition to the changes mentioned above we have added the following minor changes:

-   The citation for the XDS program package was updated;

-   Amino acid boundaries for Mical-1 and the wavelength of data collection were included in the data statistics table for x-ray crystallography;

-   Scale bars have been added in [Figure 3](#fig3){ref-type="fig"};

-   The acknowledgments have been updated;

-   Minor changes in the Abstract were necessary to comply with the word limit.

[^1]: ^\*^All data sets were collected from one single crystal on beamline X10SA of the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland).

[^2]: ^†^Data collections statistics for SAD data refer to unmerged Friedel pairs.
